Powered By Bing

PROPEL is one of the world's largest repositories of patient-derived xenografts (PDXs) for adult and pediatric leukemias. Researchers may request these resources with no obligation to collaborate. PROPEL, an initiative of St. Jude Children's Research Hospital, is designed to accelerate discovery and cures for acute lymphoblastic leukemia and other types of leukemia.

View a list of publications describing the source of samples and their use in research.

Overview of tumor types and subtypes:

TUMOR TYPES

Tumor Types graph

TUMOR SUBTYPES

Tumor Types graph

> Contain 19 cases with paired Diagnosis-Relapse samples (sequencing pending)


Search and Request Available Samples

Abbreviations: AEL = acute erythroid leukemia, ALL = acute Lymphoblastic leukemia, ETP = early T-cell precursor, Luc = luciferase, MLL = mixed lineage leukemia, MPAL = mixed-phenotype acute leukemia, T/M = T/myeloid, D1 = 1st diagnosis, R1 = 1st relapse, R2 = 2nd relapse, R3 = 3rd relapse, S = 2nd relapse, X = xenograft,
NSG = NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
NSG-SGM3 = NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ

Notes: * = sequencing pending; ^ = time to engraft in weeks; ∇ = cells express bicistronic lentiviral vector that expresses luciferase and YFP.

To request up to five (5) samples or xenografts, check the boxes in the far right column then click the "Request Samples" button at the bottom right corner of the page. For best viewing of interactive heatmaps, please use Chrome or Firefox browsers.

Explore genomic data for both diagnosis and xenograft samples »

You may also navigate to genomic data by clicking on genomic link associated with each sample.

Sample ID Tumor Type Tumor Subtype Patient Age at Diagnosis, Years Luc Marked ∇ Species Engrafted Time, Weeks ^ Primary Sample Driving Lesion Patient Sample Other Gene Alterations Published Genomic Data Ex Vivo Screen Request Sample

Publications

  • Alexander, T. B., et al. "The genetic basis and cell of origin of mixed phenotype acute leukaemia." Nature 562(7727): 373-379, 2018.

  • Roberts, K. G., et al. "Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL." Blood Adv 1(20): 1657-1671, 2017.

  • Iacobucci, I., et al. "Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia." Cancer Cell 29(2): 186-200, 2016.

  • Gu, Z., et al. "Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia." Nat Commun 7: 13331, 2016.

  • Zhang, J., et al. "Deregulation of DUX4 and ERG in acute lymphoblastic leukemia" Nat Genet 48(12): 1481-1489, 2016.

  • Holmfeldt L, Mullighan CG. Generation of Human Acute Lymphoblastic Leukemia Xenografts for Use in Oncology Drug Discovery. Current protocols in pharmacology: John Wiley & Sons, Inc.; 2015.

  • Churchman, M. L., et al. "Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia." Cancer Cell 28(3): 343-356, 2015.

  • Maude, S. L., et al. "Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia." Blood 125(11): 1759-1767, 2015.

  • Roberts, K. G., et al. "Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia." N Engl J Med 371(11): 1005-1015, 2014.

  • Holmfeldt, L., et al. "The genomic landscape of hypodiploid acute lymphoblastic leukemia." Nat Genet 45(3): 242-252, 2013.

Request Samples